Today: 4 April 2026
Subscribe
Browse Category

Stock Market 24 October 2025

OpenAI Unveils ChatGPT Atlas Browser — Google Shares Tumble in AI Search Showdown

OpenAI’s ChatGPT Atlas Browser Takes on Chrome – Privacy Alarm and Stock Market Whiplash

OpenAI launched ChatGPT Atlas, an AI-powered browser for macOS, on October 21, 2025. Atlas embeds ChatGPT in every tab and offers an optional “browser memory” to recall visited sites and tasks. Privacy advocates warn the feature could outpace Chrome in data collection, calling it a “privacy nightmare.” Alphabet shares fell 2–3% on launch day as investors reacted to potential threats to Google’s search dominance.
24 October 2025
··
IBM Stock Soars on Quantum Breakthrough and AI Revival – Key Updates (Sept 25, 2025)

Quantum Surprise: IBM Runs 10× Faster Error‐Correction on AMD Chips, Stocks Skyrocket

IBM said Oct. 24 it ran a quantum error-correction algorithm on a standard AMD FPGA chip, achieving speeds ten times faster than required. The work, completed a year ahead of schedule for IBM’s Starling quantum computer, sent IBM shares up 8.2% and AMD to a record high. IBM and AMD began their quantum supercomputing partnership in August. IBM is competing with Microsoft and Google in quantum advances.
24 October 2025
···
Stock Market on Edge: U.S. Futures Slide as US-China Trade War Heats Up

Stocks Surge on Cooling Inflation – Fed Cuts Loom, Experts Warn of Bubble

U.S. stocks surged after September CPI data showed inflation at 3.0%, below forecasts. The Nasdaq rose 0.9% and the S&P 500 gained 0.6% on Oct. 23, nearing record highs. Investors now fully expect a 25 bp Fed rate cut at the Oct. 28–29 meeting. Tech and AI stocks, including Nvidia and Palantir, led gains.
24 October 2025
········
Oracle’s ‘Truly Awesome’ AI Cloud Quarter Sends Stock Soaring 36%, Making Ellison World’s Richest

Oracle (ORCL) Stock Surges on AI Frenzy – Trillion-Dollar Dreams in Focus

Oracle shares closed at $285.72 on Oct. 24, up 2% after rebounding from a mid-October selloff. The stock is up about 70–75% year-to-date, driven by major AI and cloud deals, including a $300 billion OpenAI contract. Oracle’s cloud backlog stands near $455 billion. Analysts have raised price targets, with consensus in the $300–$324 range.
24 October 2025
···
Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Apple (AAPL) Stock Rockets to Record High on iPhone 17 Hype — What’s Next?

Apple shares closed at a record $262.24 on Oct. 20, then opened at $259.58 on Oct. 24, surpassing the previous high set in December 2024. Early iPhone 17 sales are 10–14% above last year, fueling speculation of a new upgrade cycle. Wall Street targets range widely, with some analysts projecting $300-plus and others warning of overvaluation. Apple reports Q4 earnings Oct. 30, with forecasts near $101 billion in revenue.
24 October 2025
···
Grindr Stock Skyrockets on Buyout Buzz – What Investors Need to Know

Grindr Stock Skyrockets on Buyout Buzz – What Investors Need to Know

Grindr shares surged over 25% on October 24 after its two largest shareholders proposed an $18 per share buyout, valuing the company at a 51% premium to pre-offer prices. Board chair James Lu and director Ray Zage, controlling about 60% of shares, submitted the non-binding bid and say financing is secured. Grindr’s board formed a special committee to review the offer. Trading volume spiked to nearly 6 million shares.
24 October 2025
··
Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Clover Health (CLOV) Stock Soars 18% on Analyst Upgrades, Unusual Options Buzz

Clover Health stock surged nearly 18% to about $3.79 on Oct. 24, with trading volume exceeding 15 million shares, far above its average. The price broke past both its 50-day and 200-day moving averages. Zacks upgraded the stock to Buy on Oct. 23, but overall analyst consensus remains Hold, with a 12-month price target averaging $4.03. Short interest stands at roughly 12.9% of float.
24 October 2025
·
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next?

Theriva shares surged 92% intraday Oct. 15 after its VCN-01 therapy met primary endpoints in a Phase 2b pancreatic cancer trial, then fell back following a $4 million equity raise. Median survival in a two-dose subgroup reached 14.8 months versus 11.6 for chemo alone. The company held $12.1 million cash as of June 30, 2025, funding operations into early 2026. Expanded trial results will be presented at ESMO Oct. 20.
24 October 2025
·
The $350B Shake-Up: How AI Summaries Rewire Publisher Traffic

Alphabet Stock Skyrockets to Record High, Nears $3 Trillion on AI Boom & Earnings Hype

Alphabet Inc. hit a record near $260 per share on Oct. 24, pushing its market value to about $3.1 trillion. The stock rebounded after a volatile week, buoyed by a breakthrough quantum computing announcement and a major cloud deal with Anthropic. Analysts raised price targets, with several now above $290. Alphabet reports Q3 earnings Oct. 29.
24 October 2025
···
MultiSensor AI Stock’s Wild Ride: +42% Rally on Major Deal, –50% Crash After $14M Funding

MultiSensor AI Stock’s Wild Ride: +42% Rally on Major Deal, –50% Crash After $14M Funding

MultiSensor AI shares jumped up to 100% on Oct. 23 after announcing a major U.S. deployment deal, then plunged nearly 50% the next day following news of a $14 million private share placement at $0.409 per share. As of Oct. 24 midday, the stock traded near $0.73, down 47% on the day and 32% below last year. Institutions own 82% of shares. Full-year 2024 revenue was $7.4 million with a $21.5 million net loss.
24 October 2025
···
Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Eli Lilly said Oct. 24 it will buy Adverum Biotechnologies for $3.56 per share plus a CVR worth up to $8.91, targeting Adverum’s lead gene therapy Ixo-vec for wet AMD. Adverum shares jumped 17% on the news but stayed well below the $12.47 maximum deal value. The agreement includes a $65 million secured loan to fund trials before closing. Adverum had warned its cash would run out by Q4 2025.
24 October 2025
···
Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?

Neuphoria shares plunged about 67% in after-hours trading Oct. 20 after its lead drug BNC210 failed a Phase 3 trial for social anxiety disorder. The company halted its social anxiety program, began a strategic review, and said it would cut spending. NEUP stock dropped from $15.40 to near $4.05 before rebounding to $6.70 by Oct. 24. Neuphoria reported $14.2 million in cash as of June 30 and maintains a partnership with Merck.
24 October 2025
·
Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Picard Medical Stock Plummets 75% on Dilution Alert — What’s Driving the Crash?

Picard Medical stock plunged about 75% to $3.27 by mid-day Oct. 24, after hitting a 52-week high of $13.68 the previous day. The selloff followed an SEC filing authorizing up to 18 million new shares, raising dilution fears. The company recently reported 207% Q2 revenue growth and completed a $19.5 million IPO in September. Analysts cite uncertainty over future growth and dilution.
24 October 2025
·
General Dynamics Stock Rockets to Record High on Blowout Q3 Results and Defense Windfall

General Dynamics Stock Rockets to Record High on Blowout Q3 Results and Defense Windfall

General Dynamics reported Q3 2025 revenue of $12.91 billion, up 10.6% year-over-year, and EPS of $3.88, beating forecasts. Gulfstream jet deliveries rose to 39 from 28, driving a 30% jump in aerospace revenue. The company ended the quarter with a $167.7 billion backlog and won major new defense contracts. GD shares climbed to around $353 after hours, up 27% year-to-date.
24 October 2025
···
NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device

NeurAxis announced FDA 510(k) clearance for its PENFS device to treat adult functional dyspepsia on Oct. 24, marking the first approved therapy for this condition. NRXS shares rose to $3.82 on Oct. 23 and traded higher pre-market after the news. The company recently raised $5 million and expanded insurance coverage to 53 million lives. Q2 revenue grew 46% year-over-year; analyst sentiment remains mixed.
24 October 2025
··
Bond Yields Plunge on Cooling Inflation – Fed Cuts and Stock Rally in Play?

Bond Yields Plunge on Cooling Inflation – Fed Cuts and Stock Rally in Play?

U.S. consumer inflation rose 3.0% year-on-year in September, slightly below forecasts, prompting markets to fully price in a Fed rate cut next week. The 10-year Treasury yield fell below 4% and the dollar weakened on the news. S&P 500 futures jumped about 1%, lifting stocks toward record highs. Financials outperformed, while homebuilders and utilities lagged.
24 October 2025
···
Stocks Rocket on Cooling Inflation Data; Tech Stocks & Fed Speeches in Spotlight

Stocks Rocket on Cooling Inflation Data; Tech Stocks & Fed Speeches in Spotlight

US September CPI rose 3.0% year-on-year, below the 3.1% forecast, fueling a Wall Street rally and bets on a Fed rate cut next week. Nasdaq gained 0.9%, S&P 500 rose 0.6%, and Dow added 0.3% on October 23. Philadelphia Fed manufacturing index plunged to −12.8 in October from +23.2. Oil prices spiked on new sanctions, while gold eased from record highs.
24 October 2025
···
Stocks Rally as U.S. Inflation Cools – Asia Joins Global Rally, Fed Cut Seen as Lock

Stocks Rally as U.S. Inflation Cools – Asia Joins Global Rally, Fed Cut Seen as Lock

U.S. consumer prices rose 0.3% in September, below forecasts, with core CPI up 0.2%. Wall Street futures climbed after the data; Dow E-mini futures gained 0.5%, S&P 500 E-minis 0.7%, and Nasdaq 100 E-minis 0.98%. Intel surged 8% pre-market on strong earnings, while Deckers Outdoor dropped 11.5% after cutting guidance. Fed futures now price in a 25bp rate cut at next week’s meeting.
24 October 2025
·······
1 … 1,282 1,283 1,284 1,285 1,286 … 1,371

Stock Market Today

  • UK Shares: £5,000 Invested Five Years Ago Worth Up to £23,000
    April 4, 2026, 3:49 AM EDT. A £5,000 investment in UK shares five years ago has yielded varied returns across indexes. The FTSE 100, comprising large-cap stocks, gained 78.2%, growing the investment to nearly £8,910. In contrast, the FTSE 250 and FTSE All-Share showed more modest returns of 14.1% and 65.7%, respectively. Smaller companies often depend more on domestic conditions, explaining their weaker performance amid a sluggish UK economy. However, stock picker success stories exist. Goodwin (LSE:GDWN), a small-cap firm, rose almost 300% despite a recent 48% sell-off after losing two contract tenders. Including dividends, returns approach 360%, turning £5,000 into about £23,000. Although market reaction may be severe, Goodwin's underlying order book remains strong, supported by defence and nuclear sectors. The stock traded at a high earnings premium before the setback.
Go toTop